DOD Biotech PCL

DOD Biotech maintains a strong liquidity position with a current ratio of 4.28, indicating the company can easily cover its short-term liabilities with its current assets. The company's cash and equivalents amount to THB 129,228,520, which supports its operational flexibility and financial stability. The debt-to-equity ratio of 0.07 suggests a conservative capital structure with minimal reliance on debt financing, further reinforcing its liquidity profile. In terms of profitability, DOD Biotech's return on equity (ROE) of 6.22% and return on assets (ROA) of 5.16% are in line with the industry's preferred metrics, which emphasize efficient use of equity and asset base to generate returns. The company's operating income of THB 44,303,900 and net income of THB 59,586,790 reflect a healthy margin structure, although the gross profit margin of 34.5% is a key area to monitor for sustainability. The company's revenue is primarily concentrated in the supplementary business segment, which accounts for the majority of its operations. While the company has several subsidiaries, including DOD Healthy Life Co., Ltd. and Siam Herbal Tech Co., Ltd., the geographic exposure remains primarily within Thailand, with no significant international revenue streams disclosed. This concentration may pose a risk in the event of local economic or regulatory changes. DOD Biotech's growth trajectory is supported by a stable revenue base of THB 608,983,640 and a positive free cash flow of THB 44,205,920. The company's capital expenditure of THB -48,883,970 indicates a focus on cost management and operational efficiency rather than aggressive expansion. The outlook for the current fiscal year is stable, with no significant revenue growth expected in the near term. The risk assessment for DOD Biotech indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves mitigate financial risk. However, the lack of international diversification and reliance on a single primary business segment could expose the company to market-specific risks. Recent events and filings do not indicate any material changes in the company's operations or financial strategy. The company continues to focus on its core business of food supplements and health drinks, with no significant new product launches or strategic acquisitions disclosed in the latest financial reports.